ST PHARM

ST PHARM
IR BOOK

2026 2nd Quarter Earnings Release

Cautionary Statement regarding Forward-looking Statements

This presentation contains forward-looking statements from ST Pharm (“the company”) that include, but are not limited to, statements regarding our future financial performance, business strategies, market opportunities, product development, and operational plans. Words such as “anticipate,” “believe,” “estimate,” “expect,” “intend,” “may,” “plan,” “project,” “will,” and similar expressions are intended to identify such forward-looking statements.

These forward-looking statements are based on our current expectations and beliefs concerning future developments and their potential effects on the company. Such forward-looking statements are inherently subject to risks, uncertainties, and assumptions that could cause actual results to differ materially from those expressed in these forward-looking statements.

We caution investors not to place undue reliance on any forward-looking statements. These statements speak only as of the date they are made, and we undertake no obligation to publicly update or revise any forward-looking statements, whether as a result of new information, future events, or otherwise, except as required by law. Additionally, please note that the financial figures and metrics presented in these Investor Relations materials are preliminary and have not yet been audited by an independent auditor. These numbers may be subject to change in future finalized disclosures.

2026 2nd Quarter Financial Results

Preliminary Consolidated Earnings

(Unit : 1 Billion KRW)



* "Etc." includes revenues from CRO subsidiaries, mRNA, etc.

Statement

(Unit : 1 Billion KRW)

Revenue ₩108.5 Billion, OP ₩18.3 Billion, NI ₩13.2 Billion

1) Growth driven by strong commercial-stage sales & broadening clinical-stage sales
2) Margin pressured by clinical project with high carrying cost (one-off in nature)
3) Profitability tailwind expected in 2H with Plant 2 L-line's higher utilization rate

	'26.2Q	'25.2Q	2025	YoY
Revenue	**108.5**	**68.3**	**331.7**	*58.9%*
Cost of Goods Sold	69.4	36.2	195.5	*91.4%*
Gross Profit	39.1	32.0	136.2	*22.2%*
SG&A Expenses	20.8	19.1	81.3	*9.0%*
R&D Expenses	7.3	6.1	23.7	*19.5%*
Operating Profit	**18.3**	**12.9**	**54.9**	*41.7%*
Net Income	**13.2**	**5.4**	**54.6**	*145.0%*
Gross Profit Margin	*36.1%*	*46.9%*	*41.1%*	*-10.8%p*
Operating Profit Margin	*16.9%*	*18.9%*	*16.6%*	*-2.1%p*
Net Income Margin	*12.1%*	*7.9%*	*16.5%*	*4.3%p*

2026 2nd Quarter Financial Results

Segment Breakdown

(Unit : 1 Billion KRW)

Segments		'25.2Q	'25.3Q	'25.4Q	'26.1Q	'26.2Q	YoY
Oligo	**Total**	**43.5**	**68.6**	**87.9**	**40.0**	**79.6**	*83.1%*
	Comm.	37.2	34.1	70.6	27.1	49.7	*33.6%*
	Clinical	6.3	34.5	17.4	12.9	29.9	*375.6%*
Small Molecule		6.7	0.1	18.4	4.7	17.5	*162.1%*
mRNA		0.7	1.4	0.4	0.7	0.1	*-91.1%*
Generic		8.9	2.5	9.3	10.5	2.4	*-73.0%*
Separate		**59.8**	**72.6**	**116.1**	**56.0**	**99.6**	*66.5%*
Subsidiaries		8.4	9.3	13.0	10.9	8.9	*5.2%*
Consolidated		**68.3**	**81.9**	**129.1**	**67.0**	**108.5**	*58.9%*

Backlog Trend

(Unit : 1 Million USD)



Statement

Segment Details

- Oligonucleotide CDMO
  Commercial project sales accounted for 62%
  Secured 8 new projects in 1H. Target +7 new projects in 2H
  First Conjugation project secured

- Small Molecule CDMO
  Steady growth of sales from 2 commercial-stage projects
  Expect gradual growth in volume and order in the coming quarters

Backlog Status

- Commercial projects represent 80% of total backlog
- Oligo backlog valued at 233.1 Mil. USD, SM at 48.5 Mil. USD

Anticipated Events

- STP0404 Ph2a detailed results to be presented at academic conference

* Backlog may be subject to change depending on future currency exchange rates assumptions, shipment schedule, etc. (Assume constant rate of 1 CHF = 1.2 USD)

ST PHARM

Thank You